Pharsight

Sorilux is owned by Mayne Pharma.

Sorilux contains Calcipotriene.

Sorilux has a total of 2 drug patents out of which 0 drug patents have expired.

Sorilux was authorised for market use on 06 October, 2010.

Sorilux is available in aerosol, foam;topical dosage forms.

Sorilux can be used as use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older, use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older.

The generics of Sorilux are possible to be released after 07 May, 2028.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128	MAYNE PHARMA	Vitamin formulation	May, 2026 (3 years from now)
US8263580	MAYNE PHARMA	Vitamin formulation	May, 2028 (5 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Nov 5, 2022

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM;TOPICAL